bullish

APAC Healthcare Weekly (Jan 19)- Samsung Biologics, Daiichi Sankyo, Eisai, Sun Pharma, Biocon

393 Views19 Jan 2025 08:30
APAC healthcare companies got approvals for new products as well as clinical trials. The companies continued with acquisitions and collaborations to strengthen market position.
What is covered in the Full Insight:
  • Samsung Biologics Secures Record Contract
  • FDA Filings and Approvals
  • Sun Pharma's Strategic Acquisitions
  • AI in Drug Development and Innovation
  • Upcoming Healthcare Earnings and Events
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
x